H. Lundbeck A/S

Stories

Lundbeck trial shows VYEPTI helps migraine patients who failed other CGRP drugs

Develops and markets VYEPTI (eptinezumab); sponsored the THRIVE trial

Migraine patients who try one CGRP-blocking drug and don't get relief now have evidence that switching to a different one can work. Lundbeck's Phase IV THRIVE trial found that after 24 weeks on VYEPTI (eptinezumab), 60% of participants reported being 'much improved' or 'very much improved.'

Updated Oct 1

Alkermes enters sleep medicine market through Avadel acquisition

Money Moves

Lost bidding war for Avadel

Alkermes, a neuroscience-focused pharmaceutical company, completed its $2.37 billion acquisition of Avadel Pharmaceuticals on February 12, 2026, gaining immediate entry into the sleep medicine market. The deal adds LUMRYZ, the only once-nightly narcolepsy treatment, to Alkermes' portfolio alongside an emerging pipeline of orexin-based therapies.

Updated May 27